Risks 14th July reported that the National Institute for Health and Clinical Excellence (NICE), which has been referred to by some health professionals and the National Institute for Curtailing Expenditure, has reversed its decision to block a drug for people with asbestos related cancer.
Following a high profile campaign by asbestos groups and unions, Alimta, a drug used in the treatment of mesothelioma is recommended for patients who are able to carry out day to day tasks but whose cancer is advanced making surgery inappropriate.
To read more visit www.tuc.org.uk/risks
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment